Comparison of real-world outcomes from combination therapies for advanced kidney cancer
Direct comparisons of combination treatments for previously untreated, advanced kidney [...]
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line treatment for metastatic kidney cancer
Treatment of advanced (metastatic) kidney cancer has improved considerably over [...]
Cabozantinib most promising for refractory metastatic kidney cancer
In a European study of second-line treatments for metastatic kidney [...]
Belzutifan plus cabozantinib combination shows promise in advanced kidney cancer
Updated results from the phase 2 LITESPARK-003 trial with belzutifan [...]
How to manage side effects to cabozantinib and nivolumab
This article gives some good advice about how to manage [...]
ASCO 2024: Treatment-free survival with cabozantinib plus nivolumab
At the American Society of Clinical Oncology Annual Meeting (ASCO) last [...]
Real world data on the use of cabozantinib plus immunotherapy in the second line
A recent study looked at the use of a combination [...]
NICE approves cabozantinib plus nivolumab for advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) has approved the [...]
METEOR study: Cabozantinib compared to everolimus in advanced kidney cancer
Cabozantinib is a tyrosine kinase inhibitor that is used [...]
ESMO 2023: Belzutifan for the treatment of advanced kidney cancer
Treatments for people with metastatic kidney cancer have changed over [...]
